The objective of the present study was to explore the relationship between mitochondrial tRNAMet mutation and development of essential hypertension in Chinese Han individuals. A total of 990 patients with essential hypertension were involved. The general data (sex, age, body mass index, onset age, and family history) and information on routine blood test, blood biochemical examination, and color Doppler echocardiography of these patients were collected. All subjects underwent venous blood drawing for seperating white blood cells and DNA extraction. Then, mitochondrial tRNAMet was amplified and sequenced after purification. The patients who carried the tRNAMet mutation were taken as the indicative cases and the controls were the patients with essential hyper-tension who did not carry the mutation. We performed a comparative analysis on the routine blood test, blood biochemical examination, color Doppler echocardiography, and other data between the indicative cases and control cases. Among the 990 essential hypertensive patients, there were 8 who carried the tRNAMet mutation, and 6 mutation sites were confirmed, including A4401G, C4410A, U4418C, A4435G, U4454C, and C4456U. Compared with the control cases, the indicative cases developed essential hypertension at earlier ages. The average levels of high density of lipoprotein cho-lesterol, left ventricular end diastolic diameter, stroke volume, and cardiac index were higher in the indicative cases than in the controls. While the average levels of hemoglobin and left ventricular ejection fraction were lower in the indicative cases than in the control cases. Among the 8 indicative cases, 5 had maternally inherited hypertension; one had paternally inher-ited hypertension; and two denied any family history of hypertension. These results indicated that the mitochondrial tRNAMet mutations might induce the changes in structure and function, which was involved in the progress of the essential hypertension by disturbing the blood metabolism, the steady-state of the blood cells, and the cardiac struc-ture and function.
LI Zong-Bin, LIU Yu-Qi, LI Pan-Hua, CHEN Rui, WANG Lin, SHU Qiang-Lei, LI Yang, WANG Shi-Wen
. Mitochondrial tRNA mutation in Chinese Han essential hypertensive individuals[J]. Hereditas(Beijing), 2011
, 33(6)
: 601
-606
.
DOI: 10.3724/SP.J.1005.2011.00601
[1] Dominiczak AF, Negrin DC, Clark JS, Brosnan MJ, McBride MW, Alexander MY. Genes and hypertension: from gene mapping in experimental models to vascular gene transfer strategies. Hypertension, 2000, 35(1): 164-172.
[2] Gharavi AG, Phillips RA, Finegood DT, Lipkowitz MS. Glycogen synthase polymorphism, insulin resistance and hypertension. Blood Pressure, 1996, 5(2): 86-90.
[3] Yang WJ, Huang JF, Ge DL, Yao CL, Duan XF, Shen Y, Qiang BQ, Gu DF. Lipoprotein lipase gene is in linkage with blood pressure phenotypes in Chinese pedigrees. Human Genetics, 2004, 115(1): 8-12.
[4] Motone M, Katsuya T, Ishikawa K, Iwashima Y, Sugimoto K, Yamamoto K, Fu Y, Matsuo A, Ohishi M, Rakugi H, Ogihara T. Association between hepatocyte growth factor gene polymorphism and essential hypertension. Hypertens Res, 2004, 27(4): 247-251.
[5] Zhao WY, Wang LY, Lu XF, Yang W, Huang JF, Chen SF, Gu DF. A coding polymorphism of the kallikrein 1 gene is associated with essential hypertension: a tagging SNP- based association study in a Chinese Han population. J Hypertens, 2007, 25(9): 1821-1827.
[6] Geller DS. A mineralocorticoid receptor mutation causing human hypertension. Curr Opin Nephrol Hypertens, 2001, 10(5): 661-665.
[7] Schwartz F, Duka A, Sun FZ, Cui J, Manolis A, Gavras H. Mitochondrial genome mutations in hypertensive individuals. Am J Hypertens, 2004, 17(7): 629-635.
[8] Fuentes RM, Notkola IL, Shemeikka S, Tuomilehto J, Nissinen A. Familial aggregation of blood pressure: a population-based family study in eastern Finland. J Hum Hypertens, 2000, 14(7): 441-445.
[9] Yang Q, Kim SK, Sun FZ, Cui J, Larson MG, Vasan RS, Levy D, Schwartz F. Maternal influence on blood pressure suggests involvement of mitochondrial DNA in the pathogenesis of hypertension: The framingham heart study. J Hypertens, 2007, 25(10): 2067-2073.
[10] Wilson FH, Hariri A, Farhi A, Zhao HY, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, Scheinman SJ, Lifton RP. A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science, 2004, 306(5699): 1190-1194.
[11] Watson B Jr, Khan MA, Desmond RA, Bergman S. Mito-chondrial DNA mutations in black Americans with hypertension-associated end-stage renal disease. Am J Kidney Dis, 2001, 38(3): 529-536.
[12] Li ZB, Liu YQ, Yang L, Wang SW, Guan MX. Maternally inherited hypertension is associated with the mitochondrial tRNAIle A4295G mutation in a Chinese family. Biochem Biophys Res Commun, 2008, 367(4): 906-911.
[13] Liu YQ, Li RH, Li ZB, Wang XJ, Yang L, Wang SW, Guan MX. Mitochondrial transfer RNAMet 4435A>G mutation is associated with maternally inherited hypertension in a Chinese pedigree. Hypertension, 2009, 53(6): 1083-1090.
[14] 刘玲玲, 谭端军, 徐斌, 薛桥, 王士雯. 原发性高血压遗传机制研究: 全线粒体基因变异扫描分析. 中国临床康复, 2004, 8(12): 2271-2274.
[15] Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol, 1986, 57(6): 450-458.
